Advertisement Body PRO Covers The 48th Annual ICAAC/IDSA 46th Annual Meeting

Diabetes Risk Appears Lower for HIV-Infected Patients Than Uninfected Patients

An Interview With Adeel A. Butt, M.D.

October 27, 2008

Multimedia Toolbox

Listen to Audio (5 min.)

Please note: These files can be quite large. Allow some time for them to download.

There's nothing like hearing the results of studies directly from those who actually conducted the research. In this interview, you'll meet one of these impressive HIV researchers and read his explanation of the study he presented at ICAAC/IDSA 2008.

I am Adeel Butt with the University of Pittsburgh Medical Center and VA Pittsburgh Healthcare System.

We looked at the risk of diabetes mellitus in HIV-infected and uninfected people.1 The study was conducted in the Veterans Aging Cohort Study, which is an ongoing, live cohort of more than 3,500 HIV-positive, and more than 3,500 HIV-uninfected, controls. What we found was that the actual prevalence of diabetes in the HIV-positive people is lower, than when compared to the HIV-negative group.


Adeel A. Butt, M.D.
Adeel A. Butt, M.D.
I think the biggest drivers of these lower rates in prevalence and risk are the traditional risk factors. For example, the mean BMI [body mass index] in the HIV-positive group was about 25. In the HIV-negative group, the mean BMI was about 28.9. This is a 4-point difference, and I think that is driving that significantly.

The other thing is, if you look at the use of antiretroviral therapy within the HIV-positive group, antiretroviral therapy is associated with a slightly higher risk for diabetes, but that risk is kind of totally mitigated by other traditional risk factors.

Could you talk a little bit about the characteristics of the patients?

This is a veterans cohort, so the patients are all veterans and about 97% of them are men. The mean age at entry in the HIV-positive group was 49.6 years and in the HIV-negative group it was 50.8 years. About 10% to 15% of them are over 60 years old, so we have a fair representation across the age groups. It's a very racially diverse cohort, with a large number of minorities included in both the HIV-positive and HIV-negative groups because of a control for that.

The HCV [hepatitis C virus] coinfection rate was about 31% in the HIV-positive group and about 15% in the HIV-negative group. The mean BMI, as I already pointed out, is about 25.2 in the HIV-positive group and 28.9 in the HIV-negative group.

It's a virologically and immunologically reasonably controlled cohort in the HIV-positive group. The median CD4 count in the HIV-positive group was 366 and the median viral load was 3 logs.

What was the relationship of drug and alcohol use to diabetes risk?

Those are not very significant. We used AUDIT-C to look at the hazards of alcohol use. It seems that there may be some protective risk overall, but it's not very clear how alcohol plays into the whole equation. But with illicit drug use, we did not find any significant association in the HIV-positive group. In the HIV-negative group there was a slight protective effect of illicit drug use. I think the odds ratio was about .67 in the HIV-negative group, and that was significant.

What's the take-home?

The take-home is that the big driver of diabetes in the HIV-positive group is still the traditional risk factors, not HIV itself. HIV itself is a relatively minor contributor at this point in time. As these people gain weight, when they go on antiretroviral therapy and are well-suppressed, their risk of diabetes might increase after that.

Thank you very much.

This transcript has been lightly edited for clarity.


  1. Butt AA, McGinnis K, Rodriguez-Barradas M, et al. HIV infection and the risk of diabetes mellitus. In: Program and abstracts of the 48th Annual ICAAC/IDSA 46th Annual Meeting; October 25-28, 2008; Washington, D.C. Abstract H-2306.

This article was provided by TheBodyPRO. It is a part of the publication The 48th Annual ICAAC/IDSA 46th Annual Meeting.

Please note: Knowledge about HIV changes rapidly. Note the date of this summary's publication, and before treating patients or employing any therapies described in these materials, verify all information independently. If you are a patient, please consult a doctor or other medical professional before acting on any of the information presented in this summary. For a complete listing of our most recent conference coverage, click here.

The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.